The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05010772
Recruitment Status : Recruiting
First Posted : August 18, 2021
Last Update Posted : June 6, 2024
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2026
Estimated Study Completion Date : December 31, 2026